US and European Narratives in Biochemical Research: How Chemists and BiotechnologistsCo-Create Knowledge in Drug Discovery

Abstract

This study is a critical examination of the comparative evolution of pharmaceutical innovation and
biotechnology in the United States and Europe from the perspectives of technological, regulatory,
and sustainability factors affecting drug discovery and development. Using a qualitative approach,
the case study analysis yielded findings to illustrate the adoption of artificial intelligence in
achieving SDGs. The primary findings are related to artificial intelligence integration,
sustainability and green chemistry, translational research, molecular innovation, and patientcentred development. Results show that the United States focuses on fast commercialisation and
investing by the business community, whereas Europe focuses on regulation, ecological
responsibility, and the research model of cooperation. Although they are divergent in terms of
institutional logics, both regions are moving towards AI-based innovation and sustainabilitydriven structures. It is pointed out in the discussion that pharmaceutical innovation is becoming
more and more multidimensional, in that it needs the convergence of ethical governance, scientific
rigour, and ecological sensitivity. The study concludes that global development in health will
require hybrid models of the United States' entrepreneurial agility and Europe's safety and
sustainability. It can be recommended to encourage across-the-Atlantic cooperation, increase AI
implementation to more ethical standards, and introduce sustainability into the lines of drug
development